Spots Global Cancer Trial Database for A Phase II Study of Anlotinib in MTC Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of Anlotinib in MTC Patients
Official Title: Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma
Study ID: NCT01874873
Conditions
Interventions
Study Description
Brief Summary: Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2 and VEGFR3. It has the obvious resistance to new angiogenesis. The trial is to explore ALTN for the effectiveness of advanced medullary thyroid carcinoma and security.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
The first hospital affiliated to fujian medical university, Fuzhou, Fujian, China
Gansu Province Tumor Hospital, Lanzhou, Gansu, China
Sun Yat-Sen University Cancer Center, Guozhou, Guangdong, China
Harbin medical university affiliated tumor hospital, Harbin, Heilongjiang, China
Jiangsu province tumor hospital, Nanjing, Jiangsu, China
Liaoning Province Tumor Hospital, Shenyang, Liaoning, China
Cancer Hospital of Fudan University, Shanghai, Shanghai, China
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Contact Details
Name: Jinwan Wang, doctor
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Pingzhang Tang, doctor
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
